期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

影响硫嘌呤类药物个体化应用的相关转运体遗传多态性的研究状况

Progress on effects of pharmacogenetics of related transporters on improving the individualized thiopurine therapy
原文传递
导出
摘要 硫嘌呤类药物作为一类常用的免疫抑制剂,其疗效和不良反应的差异与转运体的基因多态性的关系已成为研究热点,本文收集并分析了相关转运体的遗传多态性与硫嘌呤类药物疗效和不良反应的相关性报道,以期为临床硫嘌呤类药物个体化应用提供一定参考。 Thiopurines, one kind of immunosuppressant, represents an effective and widely prescribed therapy in clinic.There is a growing at-tention paid on the relationship between the individual difference of effi-cacy and side effects of thiopurines and the genetic polymorphisms of rel-evant transporters.Therefore, this review summarizes the correlation of the genetic polymorphisms of relevant transporters and efficacy and ad-verse effects of thiopurines, so as to provide theoretical guidance for indi-vidualized treatment in clinical practice.
作者 冯静 王雪丁 何勇 李丹 吴杰 沈秉正 宋金春
机构地区 武汉大学人民医院药学部 中山大学药学院临床药理研究所
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2014年第11期1065-1067,共3页 The Chinese Journal of Clinical Pharmacology
关键词 硫嘌呤类药物 基因多态性 转运体 个体差异 thiopurine genetic polymorphism transporter individual variation
分类号 R968 [医药卫生—药理学] R962 [医药卫生—药理学]
  • 相关文献

参考文献21

  • 1Zeng H, Lin ZP, Sartorelli AC. Resistance to purine and pyrimi- dine nucleoside and nucleobase analogs by the human MDR1 trans- fected routine leukemia cell line L1210/VMDRC. 06 [ J ]. Biochem Pharrnacol, 2004,68:911 - 921.
  • 2Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and es- tradiol 17 - beta - D - glucuronide by multidrug resistance protein 4. Resistance to6 - mercaptopurine and6 - thioguanine[ J]. JBiol Chem, 2001,276:33747 - 33754.
  • 3Fung KL, Gottesman MM. A synonymous polymorphism in a com- mon MDR1 ( ABCB1 ) haplotype shapes protein function [ J ]. Biochim Biophys Acta, 2009,1794 : 860 - 871.
  • 4Wang D, Johnson AD, Papp AC, et al. Multidrug resistance polypep- tide 1 (MDR1, ABCB1 ) variant 3435C > T affects mRNA stability[ J ]. Pharmacogenet C, e nomics, 2005,15:693 - 704.
  • 5Dubinsky MC, Larnothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6 - mereaptopurine therapy in inflamma- tory bowel disease [ J ]. Gastroenterology, 2000,118:705 - 713.
  • 6Mendoza JL, Ureelay E, Lana R, et al. MDR1 polymorphisms and response to azathioprine therapy in patients with Crohn's disease [ J ]. Inflamm Bowel Dis, 2007,13:585 - 590.
  • 7冯静,高翔,胡品津,李嘉丽,陈旻湖,陈白莉,何瑶,张羽,龙顺华,陈瑜君,王雪丁,黄民.多药耐药基因MDR1C1236T多态性与炎症性肠病患者的活性代谢物6-TGNs的相关性[J].中国临床药理学杂志,2012,28(5):333-337. 被引量：4
  • 8Keppler D. Muhidrug resistance proteins ( MRPs, ABCCs) : impor- tance for pathophysiolagy and drug therapy [ J ]. Handb Exp Phar- mo~ol, 2011,201:299 -323.
  • 9Wielinga PR, Reid G, Challa EE, et al. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells[ J]. Mol Pharmacol, 2002,62 : 1321 - 1331.
  • 10Krishnamurthy P, Schwab M, Takenaka K, et O1. Transporter- mediated protection against thiopurine - induced hematopoietic toxicity [ J ]. Cancer Res, 2008,68:4983 - 4989.

二级参考文献15

  • 1Travis SP,Stange EF,Lemann M,et al.European evidence basedconsensus on the diagnosis and management of Crohn's disease:Current management[J].Gut,2006;55(Suppl.1):S16-S35.
  • 2Takatsu N,Matsui T,Murakami Y,et al.Adverse reactions to aza-thioprine cannot be predicted by thiopurine S-methyltransferasegenotype in japanese patients with inflammatory bowel disease[J].J Gastroenterol Hepatol,2009;24:1258-1264.
  • 3Ban H,Andoh A,Tanaka A,et al.Analysis of thiopurine S-methyltransferase genotypes in Japanese patients with inflammatorybowel disease[J].Intern Med,2008;47:1645-1648.
  • 4Ding L,Zhang FB,Liu H,et al.Hypoxanthine guanine phosphori-bosyltransferase activity is related to 6-thioguanine nucleotide con-centrations and thiopurine-induced leukopenia in the treatment ofinflammatory bowel disease[J].Inflamm Bowel Dis,2012;18:63-73.
  • 5Zeng H,Lin ZP,Sartorelli AC.Resistance to purine and pyrimi-dine nucleoside and nucleobase analogs by the human mdr1 trans-fected murine leukemia cell line l1210/vmdrc.06[J].BiochemPharmacol,2004;68:911-921.
  • 6Ansari A,Arenas M,Greenfield SM,et al.Prospective evaluationof the pharmacogenetics of azathioprine in the treatment of inflamma-tory bowel disease[J].Aliment Pharmacol Ther,2008;28:973-983.
  • 7Dervieux T,Boulieu R.Simultaneous determination of 6-thiogua-nine and methyl 6-mercaptopurine nucleotides of azathioprine inred blood cells by hplc[J].Clin Chem,1998;44:551-555.
  • 8Hindorf U,Lindqvist M,Hildebrand H,et al.Adverse events lead-ing to modification of therapy in a large cohort of patients with in-flammatory bowel disease[J].Aliment Pharmacol Ther,2006;24:331-342.
  • 9Tang K,Ngoi SM,Gwee PC,et al.Distinct haplotype profiles andstrong linkage disequilibrium at the mdr1 multidrug transporter genelocus in three ethnic asian populations[J].Pharmacogenetics,2002;12:437-450.
  • 10Cascorbi I,Gerloff T,Johne A,et al.Frequency of single nucleo-tide polymorphisms in the P-glycoprotein drug transporter mdr1gene in white subjects[J].Clin Pharmacol Ther,2001;69:169-174.

共引文献3

中国临床药理学杂志
2014年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部